If you would like to explore the possibility of participating in a clinical trial at Guthrie, please call 1-800-836-0388.

As a Guthrie cancer patient you will have the unique opportunity to participate in one or more of some 100 clinical research trials that involve new treatments for many cancer types.

As a Guthrie patient you may have the unique opportunity to take part in clinical research trials for atrial fibrillation, congestive heart failure, 脂质紊乱, heart attack and many more cardiology disease states.

As a Guthrie patient you may have an opportunity to take part in clinical research trials for celiac disease, 克罗恩氏病, 溃疡性结肠炎, 返流性疾病, hepatitis and many more gastroenterology disease states.

Clinical trials study new ways to prevent, detect and treat disease. If you take part in research, you help advance new investigational medical therapies. 

标题: CAMBRIA-1:第三阶段, 非盲, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, 下一代, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in 病人 with ER+/HER2- Early 乳房 Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
部门: 肿瘤学
诊断: 乳房
首席研究员: Joyson Poulose, MD
Sub-Investigator (s):
赞助商: 阿斯特拉捷利康
Details (Indentifier #): NCT05774951
标题: CAMBRIA-2:第三阶段, 非盲, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, 新一代, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for 病人 with ER+/HER2- Early 乳房 Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
部门: 肿瘤学
诊断: 乳房——辅助
首席研究员: Joyson Poulose, MD
赞助商: 阿斯特拉捷利康
Details (Indentifier #): NCT04964934
标题: EA5181: 随机 Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
部门: 肿瘤学
诊断: 肺-非小细胞
首席研究员: Joyson Poulose, MD
Sub-Investigator (s):
赞助商: ECOG-ACRIN
Details (Indentifier #): NCT04092283
标题: EA6141, 随机 Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in 病人 with Unresectable Stage III or Stage IV 黑素瘤
部门: 肿瘤学
诊断: 黑素瘤
首席研究员: Joyson Poulose, MD
Sub-Investigator (s):
赞助商: ECOG-ACRIN
Details (Indentifier #): NCT02339571
标题: EA6194, Phase II 随机 Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in 病人 with Operable 黑素瘤: Efficacy and Biomarker Study
部门: 肿瘤学
诊断: 黑素瘤
首席研究员: Joyson Poulose, MD
Sub-Investigator (s):
赞助商: ECOG-ACRIN
Details (Indentifier #): NCT04708418
标题: Evaluation of clinical use of 毫不费力 Oxygen device in patients with oxygen dependence
部门: 肺
诊断: 肺-慢性阻塞性肺病
首席研究员: James J Walsh, MD, MSHA, FACP, FCCP
赞助商: 毫不费力
Details (Indentifier #): NA
标题: FRNM-008 The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
部门: 肿瘤学
诊断: 肿瘤学-概论
首席研究员: Joyson Poulose, MD
Sub-Investigator (s):
赞助商: Freenome
Details (Indentifier #): NCT05254834
标题: Interim FDG-PET/CT for PreDIcting REsponse of HER2+ 乳房 Cancer to Neoadjuvant Therapy: DIRECT trial
部门: 肿瘤学
诊断: 乳房
首席研究员: Joyson Poulose, MD
Sub-Investigator (s):
赞助商: ECOG-ACRIN
Details (Indentifier #): NCT05710328
标题: librexia - afa第三期, 随机, 双盲, Double-Dummy, 平行组, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation
部门: 心脏病学
诊断: 心脏-心律失常
首席研究员: Edo Kaluski, MD, FACC, FESC, FSCAI
赞助商: 詹森
Details (Indentifier #): NCT05757869
标题: Limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal 返流性疾病 and other gastrointestinal motility disorders. 顺式-美国- 154
部门: 胃肠病学
诊断: Gastrointestinal - 杂项
首席研究员: 托马斯J麦克唐纳，医学博士
Sub-Investigator (s):
赞助商: 詹森
Details (Indentifier #): 没有一个
显示 11-20 of 40 结果